Kodiak Sciences Inc. (KOD) Research

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Market snapshot

Symbol
KOD
Price
$36.14
Day change
+1.20%
Market cap
$1.9B
P/E ratio
-9.69x
52-week range
3.43-47.84
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$63.75

Recent news

  • Kodiak Sciences: Road To $120

    Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fueled by robust Phase 3 GLOW2 results for Zenkuda (tarcocimab), an experimental treatment aimed at retinal vascular disorders.

  • Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

    Investors appear to be responding to both the strength of the data and the possibility of a faster path toward a biologics license application, or BLA. Here's what investors need to know.

  • Kodiak Sciences shares surge after eye drug succeeds in late-stage study

    Shares of drug developer Kodiak Sciences jumped 52% before the bell on Thursday after its experimental ​drug met the main goal in a ‌late-stage study in patients with diabetes-related eye damage.

Peer companies

  • AnaptysBio, Inc. (ANAB)
  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Nurix Therapeutics, Inc. (NRIX)
  • Oculis Holding AG (OCS)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • ProKidney Corp. (PROK)
  • Tango Therapeutics, Inc. (TNGX)

Recent insider activity

  • BORGESON JOHN A. — M-Exempt (30000 shares) on 2026-06-04
  • BORGESON JOHN A. — S-Sale (25896 shares) on 2026-06-04
  • BORGESON JOHN A. — S-Sale (4104 shares) on 2026-06-04
  • BORGESON JOHN A. — M-Exempt (30000 shares) on 2026-06-04
  • BORGESON JOHN A. — M-Exempt (28614 shares) on 2026-04-15

Open Kodiak Sciences Inc. (KOD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.